Richard Tullis - Aethlon Medical Insider

AEMD -- USA Stock  

USD 1.10  0.0037  0.34%

Dr. Richard H. Tullis Ph.D. is Chief Science Officer of the Company. He was Vice President Director of Aethlon Medical Inc. Dr. Tullis has extensive biotechnology management and research experience and is the founder of Syngen Research formerly a wholly owned subsidiary of Aethlon Medical Inc. Previously Dr. Tullis cofounded Molecular Biosystems Inc. a former NYSE company. At Molecular Biosystems Dr. Tullis was Director of Oligonucleotide Hybridization Senior Research Scientist and Member of the Board of Directors. In research Dr. Tullis developed and patented the first application of oligonucleotides to antisense antibiotics and developed new methods for the chemical synthesis of DNA via methoxyhosphorochloridites. Dr. Tullis also codeveloped the first applications of covalently coupled DNAenzyme conjugates using synthetic oligonucleotides during his tenure at Molecular Biosystems. In 1985 Dr. Tullis founded and served as President and CEO of Synthetic Genetics Inc. a pioneer in custom DNA synthesis which was sold to Molecular Biology Resources in 1991. Dr. Tullis also served as interimCEO of Genetic Vectors Inc. which completed its IPO under his management and was cofounder of DNA Sciences Inc. a company that was eventually acquired by Genetic Vectors
Age: 69  VP Since 2015  Ph.D    
Tullis received his Ph.D. in Biochemistry and Cell Biology from the University of California at San Diego, and has done extensive postdoctoral work at UCSD, USC, and the University of Hawaii.

Richard Tullis Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (66.52) % which means that it has lost $66.52 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (171.99) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 841.15 K in liabilities with Debt to Equity (D/E) ratio of 13.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Aethlon Medical has Current Ratio of 14.83 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 5 records

VP Since

Dov FarkashNova Measuring Instruments Ltd
Hila MukevisiusNova Measuring Instruments Ltd
Richard RogoffRudolph Technologies
Gabi SharonNova Measuring Instruments Ltd
Robert KochRudolph Technologies

Entity Summary

Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company was founded in 1991 and is based in San Diego, California. Aethlon Medical operates under Scientific Technical Instruments classification in USA and traded on Nasdaq Capital Markets. It employs 6 people.Aethlon Medical (AEMD) is traded on Nasdaq Capital Markets in USA. It is located in 8910 University Center Lane and employs 6 people.

Aethlon Medical Leadership Team

John Marco, IR Contact Officer
Sabrina Johnson, Independent Director
James Joyce, Founder, Chairman, CEO and Secretary
Guy Cipriani, Independent Director
Franklyn Barry, Independent Director
Rodney Kenley, Pres and Director
Edward Broenniman, Independent Director
Charles Fisher, Independent Director
James Frakes, CFO and Sr. VP of Fin.
Richard Tullis, Chief Science Officer and VP
Chetan Shah, Independent Director

Stock Performance Indicators

Did you try this?

Run ETF Directory Now

ETF Directory

Find actively-traded Exchange Traded Funds (ETF) from around the world
All  Next Launch ETF Directory

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Aethlon Medical and Coherent. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Focused Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.